Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial
“…The mean and standard deviation of the time from symptom onset to presentation is considered to be comparable to other studies in which this time duration varied from at least 20 min in the WEST study and up to 12 h in the TRANSFER-AMI, [5] CARESS-AMI, [6] GRACIA-I, [18] and SIAM III [19] studies. Both groups achieved adequate results regarding the TIMI flow and MBG with no timing superiority in the first 24 hours.…”
Section: Discussionsupporting
confidence: 65%
“…For example; Cantor WJ et al, in the TRANSFER AMI defined early PCI as immediate transfer of the patients post thrombolysis and to intervene in a period less than 6 hours, [5] while Di Mario C et al [6], in the CARESS-IN AMI trial defined early PCI as performance of intervention within 3.5 hours from hospital admission [6]. The definition of early PCI group in the GRACIA-1 trial was extended up to 24 hours from thrombolysis [18].…”
Section: Discussionmentioning
confidence: 99%
“…The trials that addressed the timing issue post thromblysis (The WEST, [20] NORDISTEMI, [7] TRANSFER AMI, [5] CAPITAL AMI, [21] CARESS-IN-AMI [6] and GRACIA1 [18]) showed significant difference between comparable groups regarding the composite end point of death/reinfarction/ recurrent ischemia favoring routine early PCI group over ischemia driven delayed PCI. The advantage of routine early angioplasty over the delayed ischemia driven PCI group was shown despite the variation of time from lytic therapy to PCI which varied from 3 hours in most of these studies to 13 hours in the GRACIA 1 trial [18]. That is why when comparing the results of these studies to our work it should be put into consideration that the two groups in our study were within the optimum window of intervention post thrombolysis and this may be the explanation why there was no significant difference between the two groups regarding the composite end point.…”
Section: Very Early Versus Early Invasive Strategy After Successful Tmentioning
Background: Till this time even with superiority of primary percutaneous coronary intervention (pPCI) in the management of ST segment elevation myocardial infarction (STEMI), most of patients present to hospitals without pPCI facilities receive fibrinolytic therapy. The current recommendations support routine early invasive strategy within 24 hours.Objectives: we aimed at evaluating the best timing of invasive strategy within the first 24 hours.
Methods:The study was conducted on 60 STEMI patients who were referred to our center after successful thrombolysis. Patients were randomized into 2 groups: Very early invasive group (n=30): subjected to very early invasive strategy within 3 to 12 hours post thrombolysis. Early invasive group (n=30): subjected to early invasive strategy within 12 to 24 hours. The primary endpoints were the composite endpoints of major adverse cardiac events (MACEs). Secondary endpoints were achievement of TIMI III flow with MBG II or III. Safety endpoints were bleeding complications.Results: Both groups were homogenous regarding the demographic, clinical, and angiographic data before invasive strategy. TIMI III flow and MBG II or III were achieved in 83.3% of patients in the very early invasive group vs. 86.6% in the early group (P = 0.955). There was no difference between both groups regarding the composite endpoints MACEs (P= 0.667) or bleeding complications (P=0.528).
Conclusion:The study did not demonstrate a correlation between magnitude of benefit and timing of early PCI post successful thrombolysis in patients with STEMI. Thus, early invasive strategy could be scheduled depending on the logistics of the reference catheterization laboratory within 24 hours post thrombolysis.
“…The mean and standard deviation of the time from symptom onset to presentation is considered to be comparable to other studies in which this time duration varied from at least 20 min in the WEST study and up to 12 h in the TRANSFER-AMI, [5] CARESS-AMI, [6] GRACIA-I, [18] and SIAM III [19] studies. Both groups achieved adequate results regarding the TIMI flow and MBG with no timing superiority in the first 24 hours.…”
Section: Discussionsupporting
confidence: 65%
“…For example; Cantor WJ et al, in the TRANSFER AMI defined early PCI as immediate transfer of the patients post thrombolysis and to intervene in a period less than 6 hours, [5] while Di Mario C et al [6], in the CARESS-IN AMI trial defined early PCI as performance of intervention within 3.5 hours from hospital admission [6]. The definition of early PCI group in the GRACIA-1 trial was extended up to 24 hours from thrombolysis [18].…”
Section: Discussionmentioning
confidence: 99%
“…The trials that addressed the timing issue post thromblysis (The WEST, [20] NORDISTEMI, [7] TRANSFER AMI, [5] CAPITAL AMI, [21] CARESS-IN-AMI [6] and GRACIA1 [18]) showed significant difference between comparable groups regarding the composite end point of death/reinfarction/ recurrent ischemia favoring routine early PCI group over ischemia driven delayed PCI. The advantage of routine early angioplasty over the delayed ischemia driven PCI group was shown despite the variation of time from lytic therapy to PCI which varied from 3 hours in most of these studies to 13 hours in the GRACIA 1 trial [18]. That is why when comparing the results of these studies to our work it should be put into consideration that the two groups in our study were within the optimum window of intervention post thrombolysis and this may be the explanation why there was no significant difference between the two groups regarding the composite end point.…”
Section: Very Early Versus Early Invasive Strategy After Successful Tmentioning
Background: Till this time even with superiority of primary percutaneous coronary intervention (pPCI) in the management of ST segment elevation myocardial infarction (STEMI), most of patients present to hospitals without pPCI facilities receive fibrinolytic therapy. The current recommendations support routine early invasive strategy within 24 hours.Objectives: we aimed at evaluating the best timing of invasive strategy within the first 24 hours.
Methods:The study was conducted on 60 STEMI patients who were referred to our center after successful thrombolysis. Patients were randomized into 2 groups: Very early invasive group (n=30): subjected to very early invasive strategy within 3 to 12 hours post thrombolysis. Early invasive group (n=30): subjected to early invasive strategy within 12 to 24 hours. The primary endpoints were the composite endpoints of major adverse cardiac events (MACEs). Secondary endpoints were achievement of TIMI III flow with MBG II or III. Safety endpoints were bleeding complications.Results: Both groups were homogenous regarding the demographic, clinical, and angiographic data before invasive strategy. TIMI III flow and MBG II or III were achieved in 83.3% of patients in the very early invasive group vs. 86.6% in the early group (P = 0.955). There was no difference between both groups regarding the composite endpoints MACEs (P= 0.667) or bleeding complications (P=0.528).
Conclusion:The study did not demonstrate a correlation between magnitude of benefit and timing of early PCI post successful thrombolysis in patients with STEMI. Thus, early invasive strategy could be scheduled depending on the logistics of the reference catheterization laboratory within 24 hours post thrombolysis.
“…Diese Strategie schließt die frühe Verlegung zur Angiographie und, wenn nö-tig, PCI nach Fibrinolyse ein. Daten aus 7 RCTs mit 2355 Patienten [138,146,[154][155][156][157][158] ergaben Vorteile bezüglich weniger Reinfarkte bei früher regelhafter Verlegung zur Angiographie nach 3−6 h (bis zu 24 h) in den ersten 24 h nach Fibrinolyse im Vergleich zur reinen Verlegung auf die Rescue-PCI nach Fibrinolyse im Krankenhaus (OR 0,57; 95 %-CI 0,38-0,85). Es ergaben sich keine Vorteile bezüglich der kurzzeitigen und Einjahressterblichkeit bzw.…”
Section: Die Kombination Von Fibrinolyse Und Perkutaner Koronarintervunclassified
“…Quanto à análise dos desfechos maiores, a exemplo de publicações nacionais [9][10][11] , nota-se elevado ín-dice de sucesso do procedimento (com porcentual próximo a 90%) e baixo porcentual de eventos adversos, fato atribuído à maior experiência acumulada dos cardiologistas invasivos do Serviço de Hemodinâmica, visto que curva de aprendizado e volume de procedimentos influenciam decisivamente os resultados da ICP, como divulgado por relevante registro americano. 12 Em especial, salienta-se baixa taxa de mortalidade (3,3%), comparável à encontrada em ensaios internacionais, como a metanálise publicada por Collet et al 13 (3,8%), ressalvando-se que nos ensaios internacionais os fibrinolíticos mais utilizados foram alteplase ou reteplase e o tempo médio de realização da ICP foi extremamente precoce.…”
Section: Tabela 4 Preditores Independentes De Insucesso E De Eventos unclassified
Elective Percutaneous Coronary Intervention after Fibrinolysis: REMAT Data (Madre Teresa Registry)Background: Acute myocardial infarction (AMI) has a high morbidity and mortality and represents a public health problem. We analyzed the results and predictors of in-hospital adverse events in patients undergoing elective percutaneous coronary intervention (PCI) after fibrinolysis. Methods: Three hundred and three patients with diagnosis of AMI undergoing pharmacological reperfusion and transferred to a tertiary center for elective PCI were selected. Results: The population included mostly men (76.6%), with mean age of 59.4 + 11.1 years, 18.1% were diabetic and 86.8% were in Killip class I. Streptokinase was used in 91.7%, the mean time to perform elective PCI was 5.6 + 3.7 days after fibrinolysis and TIMI 3 flow was achieved in 74.2% of the patients. Stents were implanted in 97.7% and angiographic success was obtained in 95.3% of the cases. Mortality was observed in 3.3%, reinfarction in 3.6%, target lesion revascularization in 1.3%, and major bleedings in 2% of the patients. Multivariate analysis indicated female gender, age > 65 years, TIMI 1 flow, thrombus in the treated vessel, Killip > I and severe left ventricular dysfunction were independent predictors of in-hospital adverse events.
Conclusions:The pharmacological reperfusion strategy followed by transfer to perform elective PCI had low in-hospital adverse event rates and is an interesting alternative to primary PCI in Brazil. However, public policies are required to improve the logistics to better handle these patients and have them available to all low and medium complexity national hospitals.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.